•  11
    © 2015 Elsevier Inc.The breakthrough of induced pluripotent stem cell technology has raised the possibility that patient-specific iPSCs may become a renewable source of autologous cells for cell therapy without the concern of immune rejection. However, the immunogenicity of autologous human iPSC -derived cells is not well understood. Using a humanized mouse model reconstituted with a functional human immune system, we demonstrate that most teratomas formed by autologous integration-free hiPSCs e…Read more